Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL.

ABSTRACT: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In

SUBMITTER: Koenig F 

PROVIDER: S-EPMC10788209 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature